All In Biotech

NDA 021119 · Bausch Lomb Ireland

Visudyne

Verteporfin · Injection · Photoenhancer

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Feb 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Apr 12, 2000

Approved uses

3

Original approval plus efficacy supplements

Registered trials

90

19 Phase 3, 4 recruiting

FAERS reports

1,481

1,316 serious, 59 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 27, 2025.

VISUDYNE ® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate VISUDYNE for the treatment of predominantly occult subfoveal CNV. VISUDYNE (verteporfin for injection) therapy is a photoenhancer indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. ( 1 )

Mechanism: VISUDYNE (verteporfin for injection) therapy is a two-stage process requiring administration of both verteporfin for injection and nonthermal red light. Verteporfin is transported in the plasma primarily by lipoproteins. Once verteporfin is activated by light in the presence of oxygen, highly reactive, short-lived singlet oxygen and reactive oxygen radicals are generated. Light activation of verteporfin results in local damage to neovascular endothelium, resulting in vessel occlusion. Damaged endothelium is known to release procoagulant and vasoactive factors through the lipoxygenase...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 30, 2008 Supplement 13 · Efficacy LetterLabel
  • Aug 22, 2001 Supplement 1 · Efficacy · priority review LabelReviewLetter
  • Apr 12, 2000 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterReviewLabel
1 products under this application
  • VISUDYNE · VERTEPORFIN 15MG/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Verteporfin" as an intervention, any sponsor and status, largest first.

All 90 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • visual acuity reduced399
  • retinal haemorrhage212
  • disease progression173
  • off label use140
  • polypoidal choroidal vasculopathy134
  • choroidal neovascularisation99
  • age-related macular degeneration87
  • retinal pigment epithelial tear74
  • retinal detachment66
  • vitreous haemorrhage63
  • detachment of retinal pigment epithelium58
  • macular degeneration58

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004101
2005147
200699
200781
200869
200958
201066
2011110
201246
201318
201435
201543
201694
2017254
2018136
201956
202022
202112
20227
202311
20246
20253
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Visudyne (Verteporfin) · HCPCS J3396

2024 spending

$1.6M

Beneficiaries

851

970 claims

Per beneficiary

$1,857

2024 ASP limit $11.51 per unit

View as table
YearSpending
2020$2,648,687
2021$2,537,428
2022$1,812,800
2023$1,671,833
2024$1,580,514

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 191 on PubMed

Sponsor: Bausch Lomb Ireland

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.